IMIQUIMOD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IMIQUIMOD (IMIQUIMOD).
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 (TLR7) agonist, activating TLR7 on dendritic cells and macrophages, leading to the production of cytokines such as interferon-alpha, tumor necrosis factor-alpha, and interleukins (IL-1, IL-6, IL-8, IL-12). This enhances innate and adaptive immune responses, promoting antiviral and antitumor activity.
| Metabolism | Imiquimod is primarily metabolized by oxidation via cytochrome P450 enzymes (CYP1A1, CYP1B1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and conjugation (glucuronidation). |
| Excretion | Following topical application, systemic absorption is minimal (<0.9% of applied dose). Systemically absorbed imiquimod is primarily excreted in urine (approximately 90% as unchanged drug and metabolites) and feces (approximately 10%). |
| Half-life | The terminal elimination half-life of systemically absorbed imiquimod after topical application is approximately 30 hours (range 24-36 hours) in patients with normal renal function, supporting once-daily dosing or application three times per week. |
| Protein binding | Imiquimod is approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | The apparent volume of distribution after intravenous administration is 0.6-1.2 L/kg, indicating distribution into total body water and some tissue binding. This suggests that systemically absorbed drug is not extensively sequestered. |
| Bioavailability | Topical: Systemic bioavailability after application of 5% cream is less than 0.9% of the dose when applied to intact skin, and up to 2% when applied to disrupted skin (e.g., ulcerated lesions). No oral or parenteral formulations are available. |
| Onset of Action | Topical: Clinical effects (e.g., clearance of actinic keratosis, genital warts) are typically observed after 4-16 weeks of twice-weekly or three-times-weekly application. Local skin reactions (erythema, edema) may appear within 1-2 weeks. No parenteral or oral formulations are approved. |
| Duration of Action | Topical: Pharmacodynamic effects (cytokine induction) persist for 12-24 hours after application, prompting a dosing interval of 24 hours (once daily) or longer (three times per week). Clinical remission may persist for months after treatment completion; recurrence rates vary by condition. |
Apply 5% cream to affected area 3 times weekly (e.g., Monday, Wednesday, Friday) for up to 16 weeks; leave on skin for 8 hours.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; not dialyzable. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment due to lack of data. |
| Pediatric use | For external genital warts in patients 12 years and older: same as adult dosing. For molluscum contagiosum and other indications in children <12 years: safety and efficacy not established; clinical trials have used 5% cream 3 times weekly under medical supervision. |
| Geriatric use | No specific dose adjustment; application site reactions may be more common; monitor local skin reactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IMIQUIMOD (IMIQUIMOD).
| Breastfeeding | It is not known if imiquimod is excreted in human milk. Due to minimal systemic absorption after topical application, risk to nursing infant is likely low. Caution is advised. M/P ratio not available. |
| Teratogenic Risk | Imiquimod is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenic effects at doses up to 2 mg/kg (systemic exposure). No adequate human studies exist. Topical application results in minimal systemic absorption, so risk to fetus is considered low, but use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to imiquimod or any component of the formulation."]
| Precautions | ["Local skin reactions (e.g., erythema, edema, vesicles, erosion, ulceration) are common; avoid use on open wounds or infected skin.","Systemic flu-like symptoms (e.g., fatigue, fever, myalgia) may occur.","Risk of exacerbation of inflammatory conditions (e.g., autoimmune disorders).","Avoid sun exposure or use sun protection due to photosensitivity.","Not recommended for use during pregnancy unless clearly needed."] |
Loading safety data…
| Fetal Monitoring |
| Assess for local skin reactions at application site. Monitor for systemic symptoms such as flu-like signs, fatigue, or myalgia. No specific fetal monitoring required. |
| Fertility Effects | No known effects on human fertility. Animal studies showed no impairment of fertility at doses up to 2 mg/kg. |